The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 351 members from 87 departments and divisions based at 3 geographical sites (Rochester, MN - MGR; Jacksonville, FL - MCF; and Phoenix/ Scottsdale, AZ - MCA). Our mission is to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. MCCC, like Mayo Clinic in general, serves not only patients in the immediate geographical areas of MGR, MCF, and MCA, but also patients from throughout the USA and the rest of the world. MCCC has 10 research programs: Cell Biology; Developmental Therapeutics; Cancer Immunology & Immunotherapy; Gene & Virus Therapy; Women's Cancer; Gastrointestinal Cancer; Hematologic Malignancies; Neuro-oncology; Genetic Epidemiology & Risk Assessment; and Cancer Prevention & Control. Research is facilitated by: 1) 13 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Biospecimens Accessioning & Processing, Pathology Research Core, Transgenic & Knockout Core, Proteomics, Microscopy & Cell Analysis, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis; and 2) clinical support management activities including Clinical Trials Office, PRMS, and Data & Safety Monitoring. Since the last renewal, MCCC has grown with an increase in overall peer-reviewed funding from $105.9M to $123.6M and an increase in NCI funding from $75.7M to $92.7M. Of particular note is a new Ovarian SPORE and a new training grant. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Brain, Breast, Pancreas), as well as several multi-disciplinary and training grants. Research productivity and excellence is demonstrated by high-impact clinical and scientific publications - several of which have led to changes in cancer care. As the MCCC moves forward, a major cross-programmatic effort will be to build on research started during the past grant period in the cancer genome with the development of new genome-guided therapy approaches.

Public Health Relevance

The Mayo Clinic Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted within Mayo Clinic. The Center's goal is to translate the discoveries in the laboratory into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with canner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-44
Application #
9437706
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications